MPLT – maplight therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Maplight Therapeutics (NASDAQ:MPLT) is now covered by analysts at Weiss Ratings. They set a "sell (e)" rating on the stock.
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 [Yahoo! Finance]
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Wall Str
Form 4 MapLight Therapeutics, For: Feb 05 Filed by: GILLIS JONATHAN
Form 4 MapLight Therapeutics, For: Feb 05 Filed by: Setia Vishwas
Form 4 MapLight Therapeutics, For: Feb 05 Filed by: Kreitzer Anatol
Form 4 MapLight Therapeutics, For: Feb 05 Filed by: Foff Erin Pennock
Form 4 MapLight Therapeutics, For: Feb 05 Filed by: Lillie James Woodruff
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.